Browse News

Found 626 articles

• Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 07, 2023

  9/7/2023

  Voyager Therapeutics, Inc. has entered into employment agreements with three newly-hired employees that, among other things, provide for the grant to such employees of non-qualified stock options and restricted stock units as inducements material to such employees’ entering into employment with Voyager.

• Voyager Therapeutics to Participate in Upcoming September 2023 Investor Conferences

  8/30/2023

  Voyager Therapeutics, Inc., a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, announced that management will participate in the following investor conferences.

• Defender Pharmaceuticals Phase 3 Motion Sickness Trial Results Selected for Presentation at 2023 Military Health System Research Symposium (MHSRS)

  8/10/2023

  Defender Pharmaceuticals, Inc. (the “Company” or “Defender”) today announced that the previously reported, positive results from its Phase 3 clinical trial with DPI-386 Nasal Gel for prevention of nausea and vomiting induced by motion in adults has been selected for presentation at the upcoming 2023 Military Health System Research Symposium (MHSRS) to be held August 14 -17, 2023 in Kissimmee, FL.

• Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 08, 2023

  8/8/2023

  Voyager Therapeutics, Inc., a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has entered into an employment agreement with Beth Shafer, Ph.D., M.A., M.Phil. that, among other things, provides for the grant to Dr. Shafer of a non-qualified stock option and restricted stock units as an inducement material to Dr. Shafer’s entering into employment with Voyager as Voyager’s Chief Business Officer.

• Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results

  8/8/2023

  Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2023 financial results.

• Voyager Therapeutics Announces Appointment of Beth Shafer as Chief Business Officer

  8/7/2023

  Voyager Therapeutics, Inc. today announced the appointment of Beth Shafer, Ph.D., M.A., M.Phil., as Chief Business Officer (CBO).

• Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results

  8/3/2023

  Voyager Therapeutics, Inc., a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, reported second quarter 2023 financial and operating results.

• Voyager Therapeutics to Present at the Canaccord Genuity Growth Conference

  8/2/2023

  Voyager Therapeutics, Inc. today announced that Chief Scientific Officer Todd Carter, Ph.D., and Chief Financial Officer Peter Pfreundschuh will participate in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference on Thursday, August 10, 2023, at 10:30 a.m. ET.

• Neurocrine Biosciences Reports Second Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance

  8/1/2023

  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2023 and raised net sales guidance for INGREZZA in 2023.

• Voyager Therapeutics Announces Second Quarter 2023 Conference Call and Webcast

  7/27/2023

  Voyager Therapeutics, Inc. today announced it will report second quarter 2023 financial and operating results before the market opens on Thursday, August 3, 2023.

• Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

  7/26/2023

  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six months ended June 30, 2023, and provided an update on its clinical pipeline and other corporate developments.

• New Clinical and Real-World Data for Genentech’s Vabysmo at ASRS Reveal Improved Outcomes for People With Two Leading Causes of Vision Loss

  7/20/2023

  Genentech, a member of the Roche Group, announced that data from its ophthalmology portfolio will be highlighted in 25 abstracts at the 2023 American Society of Retina Specialists Annual Meeting, which will be held from July 28 to August 1 in Seattle, WA.

• EMulate Therapeutics Announces the Publication of Its Phase I/II Results in CNS Oncology: “An Expanded Safety/Feasibility Study of the EMulate Therapeutics Voyager™ System in Patients with Recurrent Glioblastoma”

  7/18/2023

  EMulate Therapeutics, Inc. (EMulate) announced today the publication of its peer-reviewed clinical trial using EMulate’s technology for the treatment of glioblastoma in the Journal CNS Oncology https://www.futuremedicine.com/doi/10.2217/cns-2022-0016.

• 

  Untangling the Amyloid-Tau Connection to Inform New Drug Development

  7/14/2023

  Recent data from the Phase III study of donanemab emphasize a correlation between amyloid and tau. Experts say a greater understanding of this link could further Alzheimer's drug development.

• Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 11, 2023

  7/11/2023

  Voyager Therapeutics, Inc. has entered into employment agreements with Jacquelyn Fahey Sandell and another newly hired employee that, among other things, provide for the grant to such employees of non-qualified stock options and restricted stock units as inducements material to such employees’ entering into employment with Voyager.

• Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer

  7/10/2023

  Voyager Therapeutics, Inc. today announced the appointment of Jacquelyn Fahey Sandell as Chief Legal Officer (CLO).

• Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease

  6/29/2023

  Sangamo Therapeutics, Inc. and Voyager Therapeutics, Inc. (Nasdaq: VYGR), today announced the parties have entered into a definitive license agreement for a potential treatment of prion disease.

• Seres Therapeutics and Nestlé Health Science Present Late-Breaking Data on VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe 2023

  6/17/2023

  Seres Therapeutics, Inc. and Nestlé Health Science announced the presentation of a post-hoc analysis from the Phase 3 development program for VOWST™, the first and only U.S. Food and Drug Administration -approved orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection in adults following antibacterial treatment for recurrent CDI.

• Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic

  6/14/2023

  ROCHESTER, Minn., June 14, 2023 /PRNewswire/ -- Vyriad, Inc., announces an expansion of a Phase 1 investigator-initiated trial at Mayo Clinic evaluating the safety and efficacy of Voyager-V1 (VSV-hIFNbeta-NIS) in patients with peripheral T-cell lymphoma (PTCL) following encouraging initial results1.

• Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection

  6/5/2023

  Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection.